Sunitinib丨CAS 557795-19-4

Sunitinib丨CAS 557795-19-4
Product Introduction:
Catalog No.: SS110087
CAS No.: 557795-19-4
Purity: 98% min
Product Name: Sunitinib
Certificate: ISO9001
Molecular Formula: C22H27FN4O2·C4H6O5
Molecular Weight: 532.57
Send Inquiry
Technical Parameters
Description

Hangzhou Leap Chem Co., Ltd. is one of the most professional manufacturers and suppliers of sunitinib丨cas 557795-19-4 in China. Welcome to wholesale bulk high quality chemical products at competitive price from our factory. If you have any enquiry about custom service, please feel free to email us.

 

Specifications

 

Appearance Orange solid powder
Purity 98% min
Identification H-NMR
Water 0.5% max
Melting Point 189-191 °C
Total Impurities 2% max

 

Transport Information

 

Parameter

Specification

UN Number

 

Class

 

Packing Group

 

H.S. Code

2933990099306

Stability & Reactivity

The product is chemically stable under standard ambient conditions.

Storage

Keep container tightly closed. Store in a cool and shaded area. Keep under inert gas. Store locked up.

Condition to Avoid

Exposure to air.

Package

 

 

Manufacturing Information

 

Parameter

Specification

Capacity

 

Frequency

 

Main Export Countries

 

Capacity/Batch

50kg

Experience

Production since 2015

Stock

In stock

 

 

 

Applications

 

Sunitinib is primarily used as an oral anticancer agent. It functions as a multi-targeted receptor tyrosine kinase inhibitor, used in the treatment of various cancers including renal cell carcinoma, gastrointestinal stromal tumors, and pancreatic neuroendocrine tumors. Sunitinib is also employed in preclinical and clinical research to investigate cancer signaling pathways, tumor angiogenesis, and drug resistance mechanisms.

 

Benefits

 

Sunitinib offers targeted inhibition of multiple receptor tyrosine kinases, including VEGFR, PDGFR, and KIT, which helps to suppress tumor growth, angiogenesis, and metastasis. Its oral administration improves patient compliance, and its multi-targeted action increases therapeutic efficacy against diverse tumor types. Additionally, Sunitinib has shown clinical benefits in prolonging progression-free survival and improving overall outcomes in patients with advanced cancers.

 

Conclusion

 

Sunitinib is a potent targeted anticancer drug with applications in treating multiple tumor types. Its multi-targeted mechanism and oral bioavailability make it a key therapeutic option in oncology, while its use in research continues to advance understanding of cancer biology and targeted therapy development.

 

 

Send Inquiry
Beyond Your Expectation
From Science to Life with LEAPChem
contact us